Stoke Therapeutics (STOK) Competitors $8.33 -0.41 (-4.69%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$8.41 +0.08 (+0.96%) As of 02/21/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends STOK vs. CNTA, BHC, HRMY, CGON, TARS, JANX, AGIO, NAMS, IDYA, and SDGRShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Centessa Pharmaceuticals (CNTA), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), CG Oncology (CGON), Tarsus Pharmaceuticals (TARS), Janux Therapeutics (JANX), Agios Pharmaceuticals (AGIO), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical products" industry. Stoke Therapeutics vs. Centessa Pharmaceuticals Bausch Health Companies Harmony Biosciences CG Oncology Tarsus Pharmaceuticals Janux Therapeutics Agios Pharmaceuticals NewAmsterdam Pharma IDEAYA Biosciences Schrödinger Stoke Therapeutics (NASDAQ:STOK) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, community ranking, valuation and profitability. Which has stronger valuation & earnings, STOK or CNTA? Stoke Therapeutics has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$8.78M50.26-$104.70M-$2.10-3.97Centessa Pharmaceuticals$6.85M320.10-$151.09M-$1.53-10.87 Do analysts prefer STOK or CNTA? Stoke Therapeutics currently has a consensus price target of $23.00, indicating a potential upside of 176.11%. Centessa Pharmaceuticals has a consensus price target of $25.83, indicating a potential upside of 55.34%. Given Stoke Therapeutics' higher possible upside, equities research analysts plainly believe Stoke Therapeutics is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in STOK or CNTA? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 11.3% of Stoke Therapeutics shares are owned by insiders. Comparatively, 11.6% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, STOK or CNTA? Stoke Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Does the MarketBeat Community prefer STOK or CNTA? Stoke Therapeutics received 84 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 75.66% of users gave Stoke Therapeutics an outperform vote while only 58.49% of users gave Centessa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformStoke TherapeuticsOutperform Votes11575.66% Underperform Votes3724.34% Centessa PharmaceuticalsOutperform Votes3158.49% Underperform Votes2241.51% Is STOK or CNTA more profitable? Centessa Pharmaceuticals has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -629.90%. Centessa Pharmaceuticals' return on equity of -52.13% beat Stoke Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics-629.90% -54.45% -40.77% Centessa Pharmaceuticals N/A -52.13%-38.01% Does the media favor STOK or CNTA? In the previous week, Stoke Therapeutics had 13 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 20 mentions for Stoke Therapeutics and 7 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.34 beat Stoke Therapeutics' score of 0.27 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Centessa Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryStoke Therapeutics and Centessa Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$441.24M$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-3.976.1326.4618.82Price / Sales50.26313.46457.9780.74Price / CashN/A67.8344.0437.47Price / Book2.336.747.634.64Net Income-$104.70M$138.11M$3.18B$245.69M7 Day Performance-22.00%-2.02%-1.82%-2.63%1 Month Performance-15.00%-1.54%0.22%-2.37%1 Year Performance55.41%-3.14%17.49%13.65% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STOKStoke Therapeutics3.6965 of 5 stars$8.33-4.7%$23.00+176.1%+55.4%$441.24M$8.78M-3.97100Analyst ForecastAnalyst RevisionNews CoveragePositive NewsCNTACentessa Pharmaceuticals3.3026 of 5 stars$17.07-3.1%$25.83+51.3%+59.9%$2.25B$6.85M-11.16200Insider TradeHigh Trading VolumeBHCBausch Health Companies3.8473 of 5 stars$6.15-3.6%$7.42+20.6%-15.7%$2.22B$8.76B-12.8220,270Earnings ReportNews CoverageHRMYHarmony Biosciences4.7215 of 5 stars$38.98-0.3%$55.00+41.1%+4.7%$2.22B$582.02M18.47200Analyst ForecastAnalyst RevisionNews CoverageCGONCG Oncology1.8412 of 5 stars$28.52+0.1%$63.88+124.0%-38.5%$2.17B$200,000.000.0061News CoverageTARSTarsus Pharmaceuticals1.4247 of 5 stars$50.22-3.8%$56.00+11.5%+58.8%$1.92B$17.45M-13.1850Gap UpJANXJanux Therapeutics3.1282 of 5 stars$36.37-2.2%$89.90+147.2%+174.0%$1.91B$13.05M-31.0930AGIOAgios Pharmaceuticals4.3439 of 5 stars$33.22-0.2%$56.33+69.6%+31.4%$1.89B$26.82M2.92390Earnings ReportShort Interest ↓NAMSNewAmsterdam Pharma3.2893 of 5 stars$19.91+2.6%$41.60+108.9%-13.9%$1.84B$14.09M0.004Upcoming EarningsIDYAIDEAYA Biosciences3.8329 of 5 stars$21.00+1.2%$53.58+155.2%-50.9%$1.82B$23.39M-9.0180Gap UpSDGRSchrödinger1.9488 of 5 stars$24.85+1.7%$32.11+29.2%-24.6%$1.81B$216.67M-10.62790Upcoming EarningsPositive News Related Companies and Tools Related Companies CNTA Alternatives BHC Alternatives HRMY Alternatives CGON Alternatives TARS Alternatives JANX Alternatives AGIO Alternatives NAMS Alternatives IDYA Alternatives SDGR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STOK) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STOK Stock Alerts